CYCLOSPORIN A AS THE INITIAL IMMUNOSUPPRESSIVE AGENT FOR CANINE LUNG TRANSPLANTATION

Previous studies had shown that marrow graft rejection generally did not occur in untransfused dogs given 900-rad total body irradiation and hemopoietic grafts from DLA identical littermates (only 1 of 59 rejected), but was seen in all instances after three preceding transfusions of whole blood from the marrow donor on days -24, -17, and -10 before transplantation (19 of 19 rejected). The present study was undertaken to investigate whether immunization by 3 preceding transfusions of whole blood from the DLA-identical littermate marrow donor could be abrogated by administration of the immunosuppressive agent cyclo-sporin-A, 20 mg/kg/day intramuscularly on days -5 to 0. Seven of 10 dogs showed sustained marrow engraftment. 2 failed to engraft, and 1 dog died to early to be evaluated. It was concluded that immunization to non-DLA antigens by preceding whole blood transfusions could be abrogated in most cases by a short-course of cyclosporin-A before total body irradiation and marrow transplantation, resulting in successful and sustained marrow engraftment.

Download Full-text

A prospective randomized international multi-center investigator driven study comparing tacrolimus and cyclosporin a, both in combination with MMF and steroids after lung transplantation – complete 1 year follow up of 255 patients

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-2006-925691 ◽

2006 ◽

Vol 54 (S 1) ◽

Author(s):

H Treede ◽

A Glanville ◽

W Klepetko ◽

H Reichenspurner

Keyword(s):

Lung Transplantation ◽

Cyclosporin A

Download Full-text

Cyclosporin-A abrogates transfusion-induced sensitization and prevents marrow graft rejection in DLA-identical canine littermates

Blood ◽

10.1182/blood.v60.2.524.524 ◽

1982 ◽

Vol 60 (2) ◽

pp. 524-526 ◽

Cited By ~ 9

Author(s):

R Storb ◽

HJ Deeg ◽

K Atkinson ◽

PL Weiden ◽

G Sale ◽

...

Keyword(s):

Cyclosporin A ◽

Total Body Irradiation ◽

Whole Blood ◽

Graft Rejection ◽

Marrow Transplantation ◽

Immunosuppressive Agent ◽

Blood Transfusions ◽

Marrow Graft ◽

Short Course ◽

Total Body

Abstract Previous studies had shown that marrow graft rejection generally did not occur in untransfused dogs given 900-rad total body irradiation and hemopoietic grafts from DLA identical littermates (only 1 of 59 rejected), but was seen in all instances after three preceding transfusions of whole blood from the marrow donor on days -24, -17, and -10 before transplantation (19 of 19 rejected). The present study was undertaken to investigate whether immunization by 3 preceding transfusions of whole blood from the DLA-identical littermate marrow donor could be abrogated by administration of the immunosuppressive agent cyclo-sporin-A, 20 mg/kg/day intramuscularly on days -5 to 0. Seven of 10 dogs showed sustained marrow engraftment. 2 failed to engraft, and 1 dog died to early to be evaluated. It was concluded that immunization to non-DLA antigens by preceding whole blood transfusions could be abrogated in most cases by a short-course of cyclosporin-A before total body irradiation and marrow transplantation, resulting in successful and sustained marrow engraftment.

Download Full-text

Individualizing immunosuppression in lung transplantation

Global Cardiology Science and Practice ◽

10.21542/gcsp.2018.5 ◽

2018 ◽

Vol 2018 (1) ◽

Cited By ~ 2

Author(s):

Jennifer K McDermott ◽

Reda E Girgis

Keyword(s):

Lung Transplantation ◽

Immunosuppressive Agents ◽

Immunosuppressive Agent ◽

Patient Specific ◽

Improved Outcomes ◽

Patient Will ◽

Specific Factors ◽

Dosing Strategy ◽

The Individual ◽

Rejection Rates

Immunosuppression management after lung transplantation continues to evolve, with an increasing number of agents available for use in various combinations allowing for more choice and individualization of immunosuppressive therapy. Therapeutic developments have led to improved outcomes including lower acute rejection rates and improved survival. However, a one size fits all approach for any immunosuppressive strategy may not be best suited to the individual patient and ultimately patient specific factors must be considered when designing the immunosuppressive regimen. Recipient factors including age, race, co-morbidities, immunologic risk, genetic polymorphisms, concomitant and previous pharmacotherapy, and overall immunosuppression burden should be considered. There are several significant drug-drug interactions with select immunosuppressive agents utilized in lung transplant pharmacotherapy that must be considered when choosing and devising a dosing strategy for an individual immunosuppressive agent. Herein, considerations for immunosuppression management in the individual patient will be reviewed.

Download Full-text